The purpose of the Psychiatric Genomics Consortium (PGC) is to unite investigators around the world to conduct meta- and mega-analyses of genome-wide genomic data for psychiatric disorders. This website provides information about the organization, implementation, and results of the PGC.

The PGC began in early 2007 and has rapidly become a collaborative confederation of most investigators in the field. The PGC includes over 800 investigators from 38 countries. There are samples from more than 900,000 individuals currently in analysis, and this number is growing rapidly. The PGC is the largest consortium and the largest biological experiment in the history of psychiatry.

The PGC is passionate about open, inclusive, participatory, and democratic science. Given the importance of the problems we study, we are committed to rapid progress.

From 2007-11, the PGC focused on autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), bipolar disorder (BIP), major depressive disorder (MDD), and schizophrenia (SCZ). We now include large studies of eating disorders (ED), substance use disorders (SUD), obsessive-compulsive disorder (OCD)/Tourette’s Syndrome (TS), and post-traumatic stress disorder (PTSD). Initially, the PGC focused on common single nucleotide polymorphisms (SNPs). Our focus has expanded to include copy number variation (CNV) and uncommon/rare genetic variation.

The PGC has received funding from many sources. The PGC has relied heavily on the goodwill of its members and their donated effort. The establishment and genotyping of our primary studies was funded by a wide range of national, international, and commercial funders.